| 11/28/2025 19:00 |
(Corrections / Correction of Numerical Data) Corrections to the Consolidated Financial Results for the Second Quarter of Fiscal Year 2025 (IFRS) |
| 10/28/2025 11:00 |
Corporate Governance Report |
| 10/27/2025 16:30 |
Action to Implement Management that is Conscious of Cost of Capital and Stock Price |
| 10/27/2025 15:30 |
Consolidated Financial Results for the second Quarter of Fiscal Year 2025 (IFRS) |
| 10/27/2025 15:30 |
Supplemental material for financial results for the 2nd quarter |
| 10/27/2025 15:30 |
2nd Quarter of Fiscal 2025 Financial Results |
| 10/27/2025 15:30 |
Notice Regarding Absorption-type merger of Shionogi Pharma Co., Ltd. |
| 09/25/2025 15:30 |
Notice Regarding the Execution of an Absorption-Type Company Split Agreement (Simplified Absorption-Type Split) for the Succession of Business |
| 09/01/2025 15:30 |
Notice of Acquisition of TORII PHARMACEUTICAL CO., LTD. as a Wholly-Owned Subsidiary |
| 07/28/2025 15:30 |
Supplemental material for financial results for the 1st quarter of fiscal year 2025 |
| 07/28/2025 15:30 |
Consolidated Financial Results for the First Quarter of Fiscal Year 2025 (IFRS) |
| 07/28/2025 15:30 |
1st Quarter of Fiscal 2025 Financial Results |
| 07/17/2025 15:30 |
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 06/30/2025 13:00 |
Corporate Governance Report |
| 06/30/2025 11:30 |
[Summary]Shionogi Submits sNDA for Ensitrelvir in Japan for Pediatric COVID-19 Age 6 and older |
| 06/19/2025 09:00 |
Notice of Results of Tender Offer for Shares of TORII PHARMACEUTICAL CO., LTD. (Securities Code: 4551) |
| 06/18/2025 17:00 |
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan |
| 05/30/2025 09:00 |
Acceptance of a New Drug Application for Naldemedine, a Treatment for Opioid-Induced Constipation, in China |
| 05/20/2025 08:00 |
Notice of Convocation of the 160th Annual General Meeting of Shareholders and Meeting Materials 2025 |
| 05/16/2025 15:30 |
Amendments to Articles of Incorporation |
| 05/12/2025 15:30 |
Consolidaterd Financial Resauts for Fiscal Year 2024 (IFRS) |
| 05/12/2025 15:30 |
Financial results for the year ended March 31, 2025 |
| 05/12/2025 15:30 |
FY2024 Finacial Results |
| 05/07/2025 19:05 |
Notice of the Execution of an Agreement for Company Split (Simplified Absorption-type Split) of the Pharmaceutical Business of Japan Tobacco Inc. and |
| 05/07/2025 19:05 |
Notice of Commencement of Tender Offer for Shares of TORII PHARMACEUTICAL CO., LTD. (Securities Code: 4551) |
| 04/24/2025 15:45 |
Notice of Revisions to Dividend Forecasts (Dividend Increase) |
| 04/01/2025 08:30 |
Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration |
| 03/27/2025 12:30 |
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of COVID-19. |
| 03/24/2025 18:00 |
Notice of Transition to Company with Audit and Supervisory Committee and the Candidates for Directors After the Transition |
| 03/13/2025 11:30 |
Late-Breaking at CROI 2025: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylax |
| 01/31/2025 15:30 |
Financial Results for the 3rd Quarter of FY2024 Supplement |
| 01/31/2025 15:30 |
Consolidated Finacial Results for the Third Quarter of Fiscal Year 2024 (IFRS) |
| 01/31/2025 15:30 |
3rd Quarter of Fiscal 2024 Finacial Results |
| 01/30/2025 15:30 |
Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395 |
| 01/22/2025 11:30 |
Acceptance of a New Drug Application for the COVID-19 Treatment, Ensitrelvir Fumaric Acid, in Taiwan and Conclusion of Government Stockpiling Contract |
| 01/17/2025 08:59 |
Shionogi Receives Award Through BARDA's RRPV to Advance Long-Acting Formulation of S-892216 |
| 12/23/2024 15:30 |
Notice Regarding the Dissolution of Joint Ventures and Share Transfer Agreement with Ping An Insurance (Group) Company of China, Ltd. |
